Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to InvestingPro data ...

Cantor Fitzgerald reiterated its Overweight rating and $275.00 price target for Nova Measuring Instruments (NASDAQ:NVMI), which is currently trading near its 52-week high of $266.13. The firm ...

A U.S. Senate committee voted on Wednesday to advance President Donald Trump's nominee Howard Lutnick, billionaire chairman ...

President Trump has nominated Pierre Gentin, chief legal officer of the consulting giant McKinsey & Co. since 2019, to serve ...

Donald Trump's commerce secretary nominee told his US Senate confirmation hearing Wednesday he favors "across-the-board" ...

A slew of space stocks have skyrocketed following the inauguration of President Trump, boosted by his vow to champion American space exploration during his administration. Set against this ...

Cantor Fitzgerald assumed coverage of Cidara Therapeutics (CDTX) with an Overweight rating. Cidara’s lead asset CD388, an anti-viral that targets neuraminidase, an essential surface receptor ...

Cantor Fitzgerald has a “Hold” rating and a $72.00 price objective on the stock. The consensus estimate for Palantir Technologies’ current full-year earnings is $0.20 per share. Get Palantir ...

Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Fate Therapeutics in a report issued on Tuesday ...

We recently compiled a list of the Top 12 Trending AI Stocks on Latest News and Ratings. In this article, we are going to take a look at where Oracle Corporation (NYSE:ORCL) stands against the other ...